Shots:

• The approval is based on P-III study results assessing Mvasi vs bevacizumab in patients with non-squamous NSCLC
• The study demonstrated in biosimilarity of Mvasi with bevacizumab in terms of efficacy- safety and immunogenicity
• Mvasi (bevacizumab- biosimilar) is a IgG1 mAb- binds to VEGF and inhibits the interaction of VEGF with its receptors- VEGF receptor-1 & VEGF receptor-2

Ref: Amgen| Image: Thailand Medical News